These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29028688)

  • 1. Angioedema Associated With Long-Acting Injectable Paliperidone Palmitate: A Case Report.
    Papadopoulou A; Gkikas K; Efstathiou V; Gkikas I; Kokoris S; Lagari V; Papageorgiou C; Douzenis A; Siafakas N; Rizos EN
    J Clin Psychopharmacol; 2017 Dec; 37(6):730-732. PubMed ID: 29028688
    [No Abstract]   [Full Text] [Related]  

  • 2. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic.
    Lai JK; Margolese HC
    Schizophr Res; 2019 Feb; 204():443-444. PubMed ID: 30241989
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical Neuroleptic Malignant Syndrome Associated With Paliperidone Long-Acting Injection: A Case Report.
    Langley-DeGroot M; Joshi Y; Lehman D; Rao S
    J Clin Psychopharmacol; 2016 Jun; 36(3):277-9. PubMed ID: 27043124
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-Dependent Paliperidone Associated With Angioedema.
    Yucel A; Yucel N; Ozcan H; Saritemur M
    J Clin Psychopharmacol; 2015 Oct; 35(5):615-6. PubMed ID: 26125544
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypothermia Associated With Paliperidone Depot Injection in Schizophrenia Patient: A Case Report.
    Hirapara K; Munir A; Aggarwal R
    J Clin Psychopharmacol; 2020; 40(1):86-87. PubMed ID: 31834087
    [No Abstract]   [Full Text] [Related]  

  • 7. Peripheral edema: An easily overlooked side effect of long-acting injectable paliperidone.
    Ho YC; Hu LY; Liou YJ
    Aust N Z J Psychiatry; 2021 Oct; 55(10):1023. PubMed ID: 33636990
    [No Abstract]   [Full Text] [Related]  

  • 8. Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.
    Jarema M; Bieńkowski P; Heitzman J; Parnowski T; Rybakowski J
    Psychiatr Pol; 2017 Feb; 51(1):7-21. PubMed ID: 28455891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia.
    Bioque M; Bernardo M
    Expert Opin Pharmacother; 2018 Oct; 19(14):1623-1629. PubMed ID: 30244607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of tardive dystonia associated with long-acting injectable paliperidone palmitate.
    Ma CH; Chien YL; Liu CC; Chen IM; Lin CH
    Eur Neuropsychopharmacol; 2016 Jul; 26(7):1251-2. PubMed ID: 27130697
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Blepharospasms After the Use of Long-Acting Paliperidone Injections.
    Contrucci RR; Heikens M; Beex-Oosterhuis MM
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):608-609. PubMed ID: 36251386
    [No Abstract]   [Full Text] [Related]  

  • 13. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.
    Kwon JS; Kim SN; Han J; Lee SI; Chang JS; Choi JS; Lee HJ; Cho SJ; Jun TY; Lee SH; Han C; Lee KU; Lee KK; Lee E
    Int Clin Psychopharmacol; 2015 Nov; 30(6):320-8. PubMed ID: 26196188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paliperidone palmitate three-month depot formulation: a helpful innovation with practical pitfalls.
    Hope JD; Keks NA
    Australas Psychiatry; 2018 Apr; 26(2):206-209. PubMed ID: 29359582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.
    Mirza H; Harding D; Al-Balushi N
    Sultan Qaboos Univ Med J; 2018 May; 18(2):e208-e210. PubMed ID: 30210852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement.
    Muser E; Kozma CM; Benson CJ; Mao L; Starr HL; Alphs L; Fastenau J
    J Med Econ; 2015; 18(8):637-45. PubMed ID: 25851616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Llorca PM; Cosar B; Petralia A; Corrivetti G; Hargarter L
    J Psychopharmacol; 2015 Aug; 29(8):910-22. PubMed ID: 25999398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two long-acting injectable antipsychotics for schizophrenia.
    Med Lett Drugs Ther; 2015 Nov; 57(1481):152-3. PubMed ID: 26529133
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypersexuality associated with paliperidone.
    Çayköylü A; Karslıoğlu EH; Özer İ; Köksal AG
    Exp Clin Psychopharmacol; 2018 Apr; 26(2):109-112. PubMed ID: 29389211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.